Company news

Tigermed-Jyton Supports the Approval of the First Hyaluronic Acid Sodium Composite Solution in the China Market.

Bloomage Biotech’s newly developed "Runzhi Titou" compound hyaluronic acid-based mesotherapy solution has recently obtained China’s Class III Medical Device Certification. This marks the country’s first regulatory-compliant medical aesthetic product specifically designed for “skin quality improvement”. By leveraging a scientifically optimized ratio of “high-purity hyaluronic acid (HA)” and ‘amino acids”, the product effectively addresses skin dullness and dryness, heralding a new era of "safety compliance + precision efficacy" in China’s medical aesthetics sector. 

As a scientific and technological breakthrough in medical aesthetics, this product addresses two critical industry challenges: (1) filling the market gap for compliant dermal biorevitalization agents (nutrient formulations that improve skin condition) and (2) being the first to clinically validate its skin quality enhancement efficacy through rigorous trials. Under the background of increasingly stringent industry regulation and growing consumer demand for safety, Bloomage Biotech has leveraged its integrated R&D and production system to offer a state-certified, safe option for patients.

The clinical trials were conducted in collaboration with Tigermed-Jyton’s expert team. As the first clinical study on a hyaluronic acid-based mesotherapy product in China, Tigermed-Jyton’s team overcame three major technical challenges: (1) innovative trial design, (2) standardization of photography and testing across multiple centers, and (3) establishment of an objective efficacy evaluation system. Through standardized operational procedures and environmental controls, high-quality clinical data were obtained, providing robust scientific evidence for regulatory approval. 

This collaboration not only expedited the market launch of Bloomage Biotech’s compound mesotherapy product, but also set a benchmark for the development of domestic medical aesthetic solutions, opening a new chapter in beauty and health innovation. 

About Bloomage Biotech

Bloomage Biotech (688363.SH) Founded in 2000, Bloomage Biotech is a biotechnology company rooted in global life sciences research. By focusing on two foundational—disciplines glycobiology and cell biology, the company leverages its strengths in synthetic biology driven R&D innovation and industrial translation to deliver scientific solutions for life and health.